WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, ... In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, ... WebApr 13, 2024 · The projected fair value for Cytokinetics is US$38.04 based on 2 Stage Free Cash Flow to Equity. Cytokinetics' US$34.05 share price indicates it is trading at similar levels as its fair value estimate
China Universal Asset Management Co. Ltd. Lowers Holdings in ...
WebMay 5, 2024 · Cytokinetics, Incorporated (NASDAQ:NASDAQ:CYTK) Q1 2024 Earnings Conference Call May 4, 2024 4:30 PM ETCompany ParticipantsDiane Weiser - SVP of Corporate Communications and IRRobert Blum -... WebCytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases. [3] [4] In 2004 the company … reading a heart monitor
RTW Investments, LP, Ji Xing Pharmaceuticals and Cytokinetics …
WebApr 13, 2024 · In other Cytokinetics news, CEO Robert I. Blum sold 12,500 shares of the company’s stock in a transaction on Tuesday, March 28th. The stock was sold at an average price of $35.05, for a total transaction of $438,125.00. Following the completion of the sale, the chief executive officer now owns 441,058 shares in the company, valued at ... WebMar 31, 2024 · The company in the coming months will assess measures needed for the development of its neuromuscular pipeline, Cytokinetics CEO Robert Blum said in a statement. ALS, also known as Lou Gehrig’s disease, breaks down nerve cells in the brain and spinal cord that make muscles work, leading to progressive paralysis and death. ... WebOct 22, 2024 · Robert Blum became the CEO of Cytokinetics, Incorporated ( NASDAQ:CYTK) in 2007, and we think it's a good time to look at the executive's … how to stream msnbc and cnn